gene_symbol
UNKNOWN
binding_type
antigen recognition
cytotoxicity
NO
cytotoxicity_type
INDIRECT
cytotoxicity_mechanism
Elranatamab engages CD3 on T cells to activate them while binding BCMA on tumor cells; the activated T cells kill BCMA+ tumor cells via perforin/granzyme and cytokine-mediated cytotoxicity, not CD3+ T cells.
enzyme_product
Off
epitope
Off
variant
Off
isoform
Off
hla_specific
Off
gated
Off
other_modifier
Target described as CD3 on T cells in trial; specific subunit not specified.
trial_id_tar_ref
drug_id_tar_ref
disease_id_tar_ref
nct_id_tar_ref
NCT06592222
disease_id_num_tar_ref
2531
drug_id_num_tar_ref
6758